Cell transplantation in the treatment of liver diseases

[Guest guest]

Cell transplantation in the treatment of liver diseases

Pediatric Transplantation 12 (1), 6–13.

doi:10.1111/j.1399-3046.2007.00788.x

Abstract

Cell transplantation in the treatment of liver diseases

F. Smets, M. Najimi and E. M. SokalUniversité Catholique de Louvain et Cliniques

Universitaires Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy,

Brussels, Belgium

Françoise Smets, Université Catholique de Louvain, Cliniques Universitaires

Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy, Avenue

Hippocrate 10/1301, B-1200 Brussels, Belgium

Tel.: + 32 2 764 13 87

Fax: + 32 2 764 89 09

E-mail: francoise.smets@...

Alpha1AT, alpha 1-antitrypsin; ASL, arginosuccinate lyase deficiency; Enceph,

encephalopathy; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV,

hepatitis C virus; ImmunoS, immunosuppression; LCT, liver cell transplantation;

LDL, low-density lipoprotein; LT, liver transplantation; MMF, mycophenolate

mofetil; NSAID, non-steroidal anti-inflammatory drugs; OLT, orthotopic liver

transplantation; OTC, ornithine transcarbamylase deficiency; PCR, polymerase

chain reaction; PFIC, progressive familial intra-hepatic cholestasis; Pred,

prednisolone; PT, prothrombin time; Tacro, Tacrolimus; TNF, tumor necrosis

factor.

Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver

diseases.

Pediatr Transplantation 2008: 12: 6–13. © 2008 Blackwell Munksgaard

Abstract

Abstract: The liver performs multiple functions that are essential for life, the

most crucial being its role in the body metabolism. Impairment of this function,

because of liver insufficiency, can be partially restored by medical management

but OLT remains the ultimate therapeutic treatment. Because not always indicated

or available, other alternatives are proposed such as LCT. Compared to OLT, this

procedure is less invasive, less expensive, and fully reversible. More than 50

patients have thus far benefited of this technique and are reviewed here.

Indications were multiple including inborn errors of metabolism, FHF, acute on

chronic diseases, and decompensated end-stage cirrhosis. Documented results were

encouraging, especially for metabolic disorders, with medium-term efficacy up to

two yr. Related complications were exceptional. On this basis, LCT has entered

its phase of clinical application and current indications and protocols are

detailed. Ongoing lines of research are discussed, including cell quality, stem

cell field, and rejection prevention. Further improvement of the procedure is

therefore expected and should lead to broader applications of LCT.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1399-3046.2007.00788.x

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Cell transplantation in the treatment of liver diseases

Pediatric Transplantation 12 (1), 6–13.

doi:10.1111/j.1399-3046.2007.00788.x

Abstract

Cell transplantation in the treatment of liver diseases

F. Smets, M. Najimi and E. M. SokalUniversité Catholique de Louvain et Cliniques

Universitaires Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy,

Brussels, Belgium

Françoise Smets, Université Catholique de Louvain, Cliniques Universitaires

Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy, Avenue

Hippocrate 10/1301, B-1200 Brussels, Belgium

Tel.: + 32 2 764 13 87

Fax: + 32 2 764 89 09

E-mail: francoise.smets@...

Alpha1AT, alpha 1-antitrypsin; ASL, arginosuccinate lyase deficiency; Enceph,

encephalopathy; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV,

hepatitis C virus; ImmunoS, immunosuppression; LCT, liver cell transplantation;

LDL, low-density lipoprotein; LT, liver transplantation; MMF, mycophenolate

mofetil; NSAID, non-steroidal anti-inflammatory drugs; OLT, orthotopic liver

transplantation; OTC, ornithine transcarbamylase deficiency; PCR, polymerase

chain reaction; PFIC, progressive familial intra-hepatic cholestasis; Pred,

prednisolone; PT, prothrombin time; Tacro, Tacrolimus; TNF, tumor necrosis

factor.

Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver

diseases.

Pediatr Transplantation 2008: 12: 6–13. © 2008 Blackwell Munksgaard

Abstract

Abstract: The liver performs multiple functions that are essential for life, the

most crucial being its role in the body metabolism. Impairment of this function,

because of liver insufficiency, can be partially restored by medical management

but OLT remains the ultimate therapeutic treatment. Because not always indicated

or available, other alternatives are proposed such as LCT. Compared to OLT, this

procedure is less invasive, less expensive, and fully reversible. More than 50

patients have thus far benefited of this technique and are reviewed here.

Indications were multiple including inborn errors of metabolism, FHF, acute on

chronic diseases, and decompensated end-stage cirrhosis. Documented results were

encouraging, especially for metabolic disorders, with medium-term efficacy up to

two yr. Related complications were exceptional. On this basis, LCT has entered

its phase of clinical application and current indications and protocols are

detailed. Ongoing lines of research are discussed, including cell quality, stem

cell field, and rejection prevention. Further improvement of the procedure is

therefore expected and should lead to broader applications of LCT.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1399-3046.2007.00788.x

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Cell transplantation in the treatment of liver diseases

Pediatric Transplantation 12 (1), 6–13.

doi:10.1111/j.1399-3046.2007.00788.x

Abstract

Cell transplantation in the treatment of liver diseases

F. Smets, M. Najimi and E. M. SokalUniversité Catholique de Louvain et Cliniques

Universitaires Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy,

Brussels, Belgium

Françoise Smets, Université Catholique de Louvain, Cliniques Universitaires

Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy, Avenue

Hippocrate 10/1301, B-1200 Brussels, Belgium

Tel.: + 32 2 764 13 87

Fax: + 32 2 764 89 09

E-mail: francoise.smets@...

Alpha1AT, alpha 1-antitrypsin; ASL, arginosuccinate lyase deficiency; Enceph,

encephalopathy; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV,

hepatitis C virus; ImmunoS, immunosuppression; LCT, liver cell transplantation;

LDL, low-density lipoprotein; LT, liver transplantation; MMF, mycophenolate

mofetil; NSAID, non-steroidal anti-inflammatory drugs; OLT, orthotopic liver

transplantation; OTC, ornithine transcarbamylase deficiency; PCR, polymerase

chain reaction; PFIC, progressive familial intra-hepatic cholestasis; Pred,

prednisolone; PT, prothrombin time; Tacro, Tacrolimus; TNF, tumor necrosis

factor.

Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver

diseases.

Pediatr Transplantation 2008: 12: 6–13. © 2008 Blackwell Munksgaard

Abstract

Abstract: The liver performs multiple functions that are essential for life, the

most crucial being its role in the body metabolism. Impairment of this function,

because of liver insufficiency, can be partially restored by medical management

but OLT remains the ultimate therapeutic treatment. Because not always indicated

or available, other alternatives are proposed such as LCT. Compared to OLT, this

procedure is less invasive, less expensive, and fully reversible. More than 50

patients have thus far benefited of this technique and are reviewed here.

Indications were multiple including inborn errors of metabolism, FHF, acute on

chronic diseases, and decompensated end-stage cirrhosis. Documented results were

encouraging, especially for metabolic disorders, with medium-term efficacy up to

two yr. Related complications were exceptional. On this basis, LCT has entered

its phase of clinical application and current indications and protocols are

detailed. Ongoing lines of research are discussed, including cell quality, stem

cell field, and rejection prevention. Further improvement of the procedure is

therefore expected and should lead to broader applications of LCT.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1399-3046.2007.00788.x

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Cell transplantation in the treatment of liver diseases

Pediatric Transplantation 12 (1), 6–13.

doi:10.1111/j.1399-3046.2007.00788.x

Abstract

Cell transplantation in the treatment of liver diseases

F. Smets, M. Najimi and E. M. SokalUniversité Catholique de Louvain et Cliniques

Universitaires Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy,

Brussels, Belgium

Françoise Smets, Université Catholique de Louvain, Cliniques Universitaires

Saint-Luc, Laboratory of Pediatric Hepatology and Cell Therapy, Avenue

Hippocrate 10/1301, B-1200 Brussels, Belgium

Tel.: + 32 2 764 13 87

Fax: + 32 2 764 89 09

E-mail: francoise.smets@...

Alpha1AT, alpha 1-antitrypsin; ASL, arginosuccinate lyase deficiency; Enceph,

encephalopathy; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV,

hepatitis C virus; ImmunoS, immunosuppression; LCT, liver cell transplantation;

LDL, low-density lipoprotein; LT, liver transplantation; MMF, mycophenolate

mofetil; NSAID, non-steroidal anti-inflammatory drugs; OLT, orthotopic liver

transplantation; OTC, ornithine transcarbamylase deficiency; PCR, polymerase

chain reaction; PFIC, progressive familial intra-hepatic cholestasis; Pred,

prednisolone; PT, prothrombin time; Tacro, Tacrolimus; TNF, tumor necrosis

factor.

Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver

diseases.

Pediatr Transplantation 2008: 12: 6–13. © 2008 Blackwell Munksgaard

Abstract

Abstract: The liver performs multiple functions that are essential for life, the

most crucial being its role in the body metabolism. Impairment of this function,

because of liver insufficiency, can be partially restored by medical management

but OLT remains the ultimate therapeutic treatment. Because not always indicated

or available, other alternatives are proposed such as LCT. Compared to OLT, this

procedure is less invasive, less expensive, and fully reversible. More than 50

patients have thus far benefited of this technique and are reviewed here.

Indications were multiple including inborn errors of metabolism, FHF, acute on

chronic diseases, and decompensated end-stage cirrhosis. Documented results were

encouraging, especially for metabolic disorders, with medium-term efficacy up to

two yr. Related complications were exceptional. On this basis, LCT has entered

its phase of clinical application and current indications and protocols are

detailed. Ongoing lines of research are discussed, including cell quality, stem

cell field, and rejection prevention. Further improvement of the procedure is

therefore expected and should lead to broader applications of LCT.

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1399-3046.2007.00788.x

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008